NASDAQ$CLPT
ClearPoint Neuro Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported a revenue increase of 13% year-over-year, driven by growth in functional neurosurgery navigation and therapy revenue, biologics and drug delivery revenue, and capital equipment and software revenue.
ClearPoint Neuro reported a strong third quarter with a 13% increase in revenue year-over-year, reaching $5.1 million. The company reaffirmed its full-year 2022 revenue outlook of $21.0 to $22.0 million and highlighted the European Commission's marketing authorization for Upstaza, a gene therapy treatment to be administered with ClearPoint's SmartFlow® Neuro Cannula.
- Reported quarterly revenue of $5.1 million, a 13% year-over-year increase.
- Partner PTC Therapeutics’ gene therapy treatment Upstaza™ was granted full marketing authorization by the European Commission.
- Added multiple new biologics and drug delivery partners in the quarter to bring the total to approximately 50.
- Announced multiple FDA clearances: the ClearPoint Maestro™ Brain Model, the ClearPoint Prism™ Neuro Laser Therapy System and the 2.1 version of the ClearPoint Neuro Navigation software.
Headline financials
Revenue & EPS history
ClearPoint Neuro · Revenue · Quarterly
$5.15M
Revenue by segment
ClearPoint Neuro · $2.2M total across 1 segment · Q3 2022
- Biologics and Drug Delivery$2.2M—100.0%
Forward guidance
The Company reaffirms its full year 2022 revenue outlook of between $21.0 and $22.0 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
-1.7%
Avg return
Earnings day
-1.7%
Avg return
5 days after
-2.3%
Avg return
30 days after
34%
15 / 44 earnings
Positive
+35.8%
Q2 2024
Best reaction
-24.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.9% | -12.1% | +6.9% | |
| Q4 2025 | -14.5% | -14.8% | +5.6% | |
| Q3 2025 | -13.5% | -8.3% | -25.7% | |
| Q1 2025 | -11.7% | -7.6% | -18.7% | |
| Q4 2024 | -17.5% | -22.1% | -30.5% | |
| Q3 2024 | -12.9% | -16.9% | +0.7% | |
| Q2 2024 | +35.8% | +46.6% | +78.3% | |
| Q1 2024 | +0.8% | -1.3% | -3.4% | |
| Q4 2023 | +18.9% | +18.6% | +2.8% | |
| Q3 2023 | -24.1% | -14.3% | +13.9% | |
| Q2 2023 | -5.0% | -8.9% | -20.2% | |
| Q1 2023 | -7.0% | -8.8% | -28.2% | |
| Q4 2022 | -3.3% | -4.5% | -0.5% | |
| Q3 2022 | -3.5% | +2.6% | -6.9% | |
| Q2 2022 | +10.3% | +9.6% | -14.3% | |
| Q1 2022 | +1.0% | +17.0% | +49.0% | |
| Q4 2021 | -0.1% | +6.2% | +19.0% | |
| Q3 2021 | -8.3% | -11.3% | -35.1% | |
| Q2 2021 | -17.6% | -20.2% | -13.2% | |
| Q1 2021 | +3.2% | +4.5% | +15.7% | |
| Q4 2020 | -22.8% | -14.0% | -3.9% | |
| Q3 2020 | +13.3% | +25.3% | +52.9% | |
| Q2 2020 | -2.2% | +5.3% | +12.2% | |
| Q1 2020 | -12.4% | -14.9% | +7.2% | |
| Q4 2019 | +18.8% | +13.6% | -16.3% | |
| Q3 2019 | -0.7% | +2.3% | +5.4% | |
| Q2 2019 | +5.8% | -1.2% | -1.0% | |
| Q1 2019 | +7.4% | +10.6% | +16.2% | |
| Q4 2018 | -3.1% | -3.1% | -8.3% | |
| Q3 2018 | -2.4% | -4.9% | -14.6% | |
| Q2 2018 | -2.2% | -6.6% | -20.9% | |
| Q1 2018 | -5.6% | -7.4% | -22.6% | |
| Q3 2017 | +1.5% | -8.0% | -0.4% | |
| Q2 2017 | -0.5% | +8.4% | +1.1% | |
| Q1 2017 | +0.0% | -3.9% | -43.0% | |
| Q3 2016 | +17.9% | -3.8% | -23.1% | |
| Q2 2016 | -5.9% | -15.3% | -20.7% | |
| Q2 2015 | -11.3% | — | — | |
| Q1 2015 | -5.6% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +2.4% | — | — | |
| Q2 2012 | +1.7% | — | — | |
| Q1 2013 | -0.8% | — | — | |
| Q3 2012 | +3.3% | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro